ALIGOS THERAPEUTICS INC
ALGSNASDAQTrading Snapshot
- Day Range
- $1.18 β $1.30
- 52-Week Range
- $1.18 β $13.69
- Volume (shares)
- 106,836
- Avg Volume (shares)
- β
- Shares Outstanding
- 6.2M
- Next Earnings
- 2027-03-03
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $3M
- P/E Ratio
- -0.2
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-6.34
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +65.3%
ALIGOS THERAPEUTICS INC
ALGSAbout ALIGOS THERAPEUTICS INC
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-Γ agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates
News unavailable.